Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 14/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046351 | 0.88 | TP53 (0.54) | TAS2R14PTGESTAS2R8CXCR3MEN1 | |
| SCHEMBL3052659 | 0.86 | TAS2R14 (0.47) | TAS2R14CXCR3MEN1KMT2AMRGPRX4 | |
| SCHEMBL3055017 | 0.84 | TAS2R14 (0.46) | TAS2R14CXCR3MEN1KMT2A | |
| SCHEMBL3049203 | 0.84 | KMT2A (0.42) | TAS2R14CXCR3MEN1KMT2A | |
| SCHEMBL3144652 | 0.83 | TAS2R14 (0.52) | TAS2R14CXCR3MEN1KMT2AMAPT | |
| SCHEMBL3144212 | 0.83 | KMT2A (0.46) | TAS2R14PTGESTAS2R8CXCR3MEN1 | |
| SCHEMBL3148189 | 0.80 | POLB (0.52) | LMNA | |
| SCHEMBL3148254 | 0.79 | TAS2R14 (0.54) | TAS2R14PTGESTAS2R8CXCR3MEN1 | |
| SCHEMBL3145273 | 0.79 | ALDH1A1 (0.49) | KMT2A | |
| SCHEMBL3137635 | 0.77 | GPR27 (0.47) | CXCR3KMT2AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
| EP-2074083-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008050168-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | TAS2R14 463/4885PTGES 359/4885TAS2R8 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.